Redmile Group, LLC Tcr2 Therapeutics Inc. Transaction History

Redmile Group, LLC

  • $1.53 Billion
  • Q3 2024

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
SELL
$1.0 - $1.62 $73,043 - $118,329
-73,043 Reduced 9.99%
658,336 $987,000
Q4 2022

Feb 14, 2023
SELL
$0.83 - $1.44 $301,510 - $523,103
-363,266 Reduced 33.19%
731,379 $731,000
Q1 2022

May 16, 2022
SELL
$2.4 - $4.71 $603,391 - $1.18 Million
-251,413 Reduced 18.68%
1,094,645 $3.02 Million
Q4 2021

Feb 14, 2022
SELL
$4.58 - $8.34 $11.3 Million - $20.6 Million
-2,470,651 Reduced 64.73%
1,346,058 $6.27 Million
Q3 2021

Nov 15, 2021
BUY
$8.44 - $18.35 $4.9 Million - $10.7 Million
580,900 Added 17.95%
3,816,709 $32.5 Million
Q2 2021

Aug 16, 2021
SELL
$16.41 - $24.71 $6.15 Million - $9.27 Million
-374,979 Reduced 10.38%
3,235,809 $53.1 Million
Q1 2021

May 17, 2021
BUY
$20.38 - $34.07 $15.9 Million - $26.5 Million
777,900 Added 27.46%
3,610,788 $79.7 Million
Q4 2020

Feb 16, 2021
BUY
$19.0 - $32.63 $752,400 - $1.29 Million
39,600 Added 1.42%
2,832,888 $87.6 Million
Q3 2020

Nov 16, 2020
BUY
$13.1 - $20.69 $13.5 Million - $21.3 Million
1,028,100 Added 58.24%
2,793,288 $56.8 Million
Q2 2020

Aug 14, 2020
SELL
$6.51 - $16.85 $13,671 - $35,385
-2,100 Reduced 0.12%
1,765,188 $27.1 Million
Q1 2020

May 15, 2020
SELL
$6.01 - $16.01 $191,719 - $510,719
-31,900 Reduced 1.77%
1,767,288 $13.7 Million
Q4 2019

Feb 14, 2020
BUY
$12.17 - $17.88 $108,313 - $159,132
8,900 Added 0.5%
1,799,188 $25.7 Million
Q3 2019

Nov 14, 2019
SELL
$10.15 - $19.53 $90,619 - $174,363
-8,928 Reduced 0.5%
1,790,288 $26.9 Million
Q2 2019

Aug 14, 2019
SELL
$13.64 - $20.97 $109,665 - $168,598
-8,040 Reduced 0.44%
1,799,216 $25.7 Million
Q1 2019

May 15, 2019
BUY
$15.01 - $22.15 $27.1 Million - $40 Million
1,807,256 New
1,807,256 $28.7 Million

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Redmile Group, LLC Portfolio

Follow Redmile Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email